[시장보고서]희귀 내분비질환 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년)

희귀 내분비질환 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년) - 적응증별, 약물 유형별, 투여 모드별, 유통 채널별, 지역별

Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

상품코드 : 1410592

리서치사 : Fairfield Market Research

발행일 : 2024년 01월

페이지 정보 : 영문 170 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,261,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495

￦ 12,349,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600

￦ 15,409,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

지금 전 세계적으로 유행하고 있는 비만은 다낭성난소증후군, 갑상선기능저하증과 같은 흔한 질환뿐만 아니라 시상하부장애, 쿠싱증후군과 같은 희귀질환을 포함한 다양한 내분비질환과 밀접한 관련이 있습니다.

비만 발생의 기본 메커니즘은 특정 내분비질환에 따라 다릅니다. 드문 내분비질환의 경우, 성장 호르몬 및 갑상선 기능과의 상호작용이 매우 중요하며, 많은 경우 지방 생성 및 지방세포 분화 증가와 관련이 있습니다.

전 세계 연구자들은 희귀 내분비질환의 치료 전략 평가에 적극적으로 참여하고 있으며, 특히 과체중 환자에게 초점을 맞추고 있습니다. 예를 들어, 뉴캐슬 대학의 과학자들은 다양한 병인 요인을 고려하면서 비만 발병의 자연사를 열심히 평가하고 있습니다.

종합적인 평가는 아직 이루어지지 않았지만, 연구자들은 평가 과정을 확장하고 일반적인 내분비학적 원인을 배제하고 적절한 치료법을 선택할 수있는 길을 열기 위해 임상 검사와 신체 검사를 실시하고 있습니다.

내분비질환의 희귀성으로 인해 연구자와 임상의는 신뢰할 수 있는 임상시험을 위해 충분한 환자 데이터를 수집해야 하는 과제를 안고 있습니다. Endocrine Genomics Virtual Laboratory(endoVL)는 분석 도구와 광범위한 데이터 세트에 대한 안전한 온라인 액세스를 제공함으로써 이러한 과제를 해결하고 희귀 내분비질환의 진단과 치료를 발전시킬 수 있는 공동 연구를 가능하게 합니다.

8,500건 이상의 부신종양 환자가 등록된 endoVL은 연구자들이 대규모 코호트를 활용하여 통계적으로 유의미한 분석을 할 수 있게 해줍니다. 현재 endoVL에는 25개 이상의 대규모 임상시험이 진행 중이며, 전 세계 연구 그룹이 참여하고 있습니다. 이러한 공동 연구 노력은 전 세계 희귀 내분비질환 치료 시장에서 새로운 성장 기회를 창출할 수 있는 큰 잠재력을 가지고 있습니다.

희귀 내분비질환은 종종 다기관 증상을 나타내며, 뚜렷한 병태생리학적 장애로 인해 눈에 먼저 나타나는 경우가 많습니다. 희귀 내분비질환의 안과적 증상을 인식하는 것은 신속한 진단, 치료 및 심각한 이환율과 사망률을 예방하는 데 매우 중요합니다.

생명공학 및 제약기업은 의학 연구자들과 함께 희귀 내분비질환의 안과적 증상 대응에 집중하여 이 중요한 분야의 치료법 개발 및 기술 혁신을 촉진할 것으로 기대됩니다.

본 보고서는 세계 희귀 내분비질환 치료 시장에 대해 조사했으며, 시장 개요와 함께 적응증별, 약물 종류별, 투여 모드별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 정리하여 전해드립니다.

세계의 희귀 내분비질환 치료 시장 전망, 적응증별, 금액(100만 달러), 수량(톤), 2018-2031년
세계의 희귀 내분비질환 치료 시장 전망, 약제 유형별, 금액(100만 달러), 수량(톤), 2018-2031년
세계의 희귀 내분비질환 치료 시장 전망, 투여 모드별, 금액(100만 달러), 수량(톤), 2018-2031년
세계의 희귀 내분비질환 치료 시장 전망, 유통 채널별, 금액(100만 달러), 수량(톤), 2018-2031년
세계의 희귀 내분비질환 치료 시장 전망, 지역별, 금액(100만 달러), 수량(톤), 2018-2031년

제4장 북미의 희귀 내분비질환 치료 시장 전망, 2018-2031년

제5장 유럽의 희귀 내분비질환 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 희귀 내분비질환 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 희귀 내분비질환 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 희귀 내분비질환 치료 시장 전망, 2018-2031년

제9장 경쟁 상황

투여 모드별과 약제 유형별 히트맵
제조업체와 약제 유형별 히트맵
기업의 시장 점유율 분석, 2023년
경쟁력 대시보드
기업 개요
- Novartis
- Ipsen
- Pfizer, Inc
- Teva
- EMD serono
- Novo Nordisk
- Eli Lilly
- Shire
- Amgen, Inc
- Corcept Therapeutics
- Novelion Therapeutics

제10장 부록

ksm

영문 목차

영문목차

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted by Fairfield Market Research.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

Acromegaly
Central Diabetes Insipidus
Ahumada-Del Castillo Syndrome
Hypoparathyroidism
Other Indications

Drug Type

Biologics
Organic Compounds

Mode of Administration

Injectables
Oral
Others

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Region

North Americ
Latin America
Europe
Japan
APEJ
MEA

1. Executive Summary

1.1. Global Rare Endocrine Disease Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

3.1. Global Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Acromegaly
  - 3.1.1.2. Central Diabetes Insipidus
  - 3.1.1.3. Ahumada-Del Castillo Syndrome
  - 3.1.1.4. Hypoparathyroidism
  - 3.1.1.5. Other Indications
3.2. Global Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Biologics
  - 3.2.1.2. Organic Compounds
3.3. Global Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Injectables
  - 3.3.1.2. Oral
  - 3.3.1.3. Others
3.4. Global Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Hospital Pharmacies
  - 3.4.1.2. Retail Pharmacies
  - 3.4.1.3. Online Pharmacies
3.5. Global Rare Endocrine Disease Treatment Market Outlook, by Region, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

4.1. North America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Acromegaly
  - 4.1.1.2. Central Diabetes Insipidus
  - 4.1.1.3. Ahumada-Del Castillo Syndrome
  - 4.1.1.4. Hypoparathyroidism
  - 4.1.1.5. Other Indications
4.2. North America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Biologics
  - 4.2.1.2. Organic Compounds
4.3. North America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Injectables
  - 4.3.1.2. Oral
  - 4.3.1.3. Others
4.4. North America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Hospital Pharmacies
  - 4.4.1.2. Retail Pharmacies
  - 4.4.1.3. Online Pharmacies
4.5. North America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.2. U.S. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.3. U.S. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.4. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.5. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.6. Canada Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.7. Canada Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 4.5.1.8. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

5.1. Europe Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Acromegaly
  - 5.1.1.2. Central Diabetes Insipidus
  - 5.1.1.3. Ahumada-Del Castillo Syndrome
  - 5.1.1.4. Hypoparathyroidism
  - 5.1.1.5. Other Indications
5.2. Europe Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Biologics
  - 5.2.1.2. Organic Compounds
5.3. Europe Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Injectables
  - 5.3.1.2. Oral
  - 5.3.1.3. Others
5.4. Europe Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospital Pharmacies
  - 5.4.1.2. Retail Pharmacies
  - 5.4.1.3. Online Pharmacies
5.5. Europe Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.2. Germany Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.3. Germany Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.4. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.5. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.6. U.K. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.7. U.K. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.8. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.9. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.10. France Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.11. France Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.12. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.13. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.14. Italy Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.15. Italy Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.16. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.17. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.18. Turkey Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.19. Turkey Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.20. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.21. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.22. Russia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.23. Russia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.24. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.25. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.26. Rest of Europe Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.27. Rest of Europe Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 5.5.1.28. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Acromegaly
  - 6.1.1.2. Central Diabetes Insipidus
  - 6.1.1.3. Ahumada-Del Castillo Syndrome
  - 6.1.1.4. Hypoparathyroidism
  - 6.1.1.5. Other Indications
6.2. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Biologics
  - 6.2.1.2. Organic Compounds
6.3. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Injectables
  - 6.3.1.2. Oral
  - 6.3.1.3. Others
6.4. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospital Pharmacies
  - 6.4.1.2. Retail Pharmacies
  - 6.4.1.3. Online Pharmacies
6.5. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.2. China Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.3. China Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.4. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.5. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.6. Japan Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.7. Japan Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.8. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.9. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.10. South Korea Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.11. South Korea Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.12. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.13. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.14. India Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.15. India Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.16. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.17. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.18. Southeast Asia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.19. Southeast Asia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.20. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

7.1. Latin America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Acromegaly
  - 7.1.1.2. Central Diabetes Insipidus
  - 7.1.1.3. Ahumada-Del Castillo Syndrome
  - 7.1.1.4. Hypoparathyroidism
  - 7.1.1.5. Other Indications
7.2. Latin America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Biologics
  - 7.2.1.2. Organic Compounds
7.3. Latin America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Injectables
  - 7.3.1.2. Oral
  - 7.3.1.3. Others
7.4. Latin America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospital Pharmacies
  - 7.4.1.2. Retail Pharmacies
  - 7.4.1.3. Online Pharmacies
7.5. Latin America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.2. Brazil Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.3. Brazil Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.4. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.5. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.6. Mexico Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.7. Mexico Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.8. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.9. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.10. Argentina Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.11. Argentina Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.12. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Acromegaly
  - 8.1.1.2. Central Diabetes Insipidus
  - 8.1.1.3. Ahumada-Del Castillo Syndrome
  - 8.1.1.4. Hypoparathyroidism
  - 8.1.1.5. Other Indications
8.2. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Biologics
  - 8.2.1.2. Organic Compounds
8.3. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Injectables
  - 8.3.1.2. Oral
  - 8.3.1.3. Others
8.4. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospital Pharmacies
  - 8.4.1.2. Retail Pharmacies
  - 8.4.1.3. Online Pharmacies
8.5. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.2. GCC Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.3. GCC Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.4. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.5. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.6. South Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.7. South Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.8. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.9. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.10. Egypt Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.11. Egypt Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.12. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.13. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.14. Nigeria Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.15. Nigeria Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.16. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. by Mode of Administration vs by Drug Type Heatmap
9.2. Manufacturer vs by Drug Type Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Novartis
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Ipsen
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Pfizer, Inc
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Teva
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. EMD serono
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Novo Nordisk
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Eli Lilly
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Shire
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Amgen, Inc
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Corcept Therapeutics
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. Novelion Therapeutics
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development

9.5.12.

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations